Houston biotech company gets FDA greenlight to move forward with COVID-19 stem cell treatment

coronavirus cure?

Celltex is looking into using stem cells to treat COVID-19, and the Houston biotech company just got the green light to go to trials. Photo courtesy of Celltex

A Houston-based biotech company announced last week that it has gotten the approval it was seeking from the U.S. Food and Drug Administration to continue testing its COVID-19 treatment that uses stem cells.

Celltex has received approval from its Investigational New Drug application, or IND, to look into stem cells — specifically Autologous Adipose Tissue-Derived Mesenchymal Stem Cells, or AdMSCs — and their effect on COVID-19 patients.

"The FDA's approval of our IND is not only a critical milestone for Celltex, but also for everyone who has been affected by COVID-19," says David G. Eller, Celltex chairman and CEO. "I am optimistic that our findings will result in favorable outcomes that will improve lives today and for generations to come."

Celltex has been in the stem cell business for nearly a decade and has treated patients with debilitating diseases like multiple sclerosis, Parkinson's, rheumatoid arthritis, and more. Eller says he's been considering how Mesenchymal Stem Cells, or MSCs, could be used amid the pandemic.

"Throughout the entire pandemic, MSCs have shown promise for combatting symptoms and complications associated with COVID-19, and as the nation's leading commercial MSC banking and technology company, Celltex has the unique ability to transition these initial findings into a clinical trial," Eller says.

The FDA clearance will allow for a phase two trial "that will evaluate the safety and prophylactic efficacy of AdMSCs against COVID-19," according to the release. There will be 200 patients across multiple centers that will be involved in the placebo-controlled study.

Celltex offices out of the Galleria area and has laboratory operations of its wholly-owned Mexican subsidiary are located in Hospital Galenia in Cancún, Quintana Roo, Mexico. Last year, Celltex planned an expansion into Saudi Arabia and also has a presence in Europe.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

University of Houston designs device that instantly kills COVID-19

ZAPPING COVID-19

While the world rushes to find a COVID-19 vaccine, scientists from the University of Houston have found a way to trap and kill the virus — instantly.

The team has designed a "catch and kill" air filter that can nullify the virus responsible for COVID-19. Researchers reported that tests at the Galveston National Laboratory found 99.8 percent of the novel SARS-CoV-2 — which causes COVID-19 — was killed in a single pass through the filter.

Zhifeng Ren, director of the Texas Center for Superconductivity at UH, collaborated with Monzer Hourani, CEO of Medistar, a Houston-based medical real estate development firm, plus other researchers to design the filter, which is described in a paper published in Materials Today Physics.

Researchers were aware the virus can remain in the air for about three hours, which required a filter that could quickly remove it. The added pressure of businesses reopening created an urgency in controlling the spread of the virus in air conditioned spaces, according to UH.

Meanwhile, to scorch the virus — which can't survive above around 158 degrees Fahrenheit — researchers instilled a heated filter. By blasting the temperature to around 392 F, they were able to kill the virus almost instantly.

The filter also killed 99.9 percent of the anthrax spores, according to researchers.

A prototype was built by a local workshop and first tested at Ren's lab for the relationship between voltage/current and temperature; it then went to the Galveston lab to be tested for its ability to kill the virus. Ren says it satisfies the requirements for conventional heating, ventilation and air conditioning (HVAC) systems.

"This filter could be useful in airports and in airplanes, in office buildings, schools and cruise ships to stop the spread of COVID-19," said Ren, MD Anderson Chair Professor of Physics at UH and co-corresponding author for the paper, in a statement. "Its ability to help control the spread of the virus could be very useful for society."

Medistar executives are also proposing a desk-top model, capable of purifying the air in an office worker's immediate surroundings, Ren added.

Developers have called for a phased roll-out of the device, with a priority on "high-priority venues, where essential workers are at elevated risk of exposure — particularly schools, hospitals and health care facilities, as well as public transit environs such as airplanes."

The hope, developers add, is that the filter will protect frontline workers in essential industries and allow nonessential workers to return to public work spaces.

3 Houston innovators to know this week

who's who

Houston's innovation ecosystem continues to grow. Last week, a group of startup mentors formed a new program that's a masterclass for aspiring entrepreneurs. Plus, a Houston innovator is writing the book on inclusion while another has a new partnership with a medical device company.

Steve Jennis, co-founder of Founder's Compass

Steve Jennis, along with three other Houston entrepreneurs, have teamed up to create a program based on each of their expertise that provides a launch pad for aspiring startup founders. Photo courtesy of Steve Jennis

Steve Jennis, a founder and mentor within the Houston innovation ecosystem, was thinking about opportunities for aspiring entrepreneurs. While there are several accelerators within the ecosystem, they tend to be months-long programs that might require equity.

"A few months ago it struck me that maybe there was a gap in the market between the aspiring entrepreneur," says Jennis, "and the accelerator or incubator program."

Jennis tapped a few of his fellow founder-mentors to create Founder's Compass, an online masterclass for people who have a business idea but don't know what to do next. Read more about the new program.

Denise Hamilton, founder and CEO of WatchHerWork

Denise Hamilton is publishing a book that helps guide Black Lives Matter allies to make changes that will help them change the world. Photo courtesy of WatchHerWork

After developing a long career as a corporate executive, Denise Hamilton was fielding tons of requests to lunch or coffee to "pick her brain." While she loved helping to mentor young businesswomen, it was starting to become exhausting. "Frankly, there weren't enough hours in the day," she says on this week's episode of the Houston Innovators Podcast.

So, five years ago, she turned the cameras on and started a library of advice from female executives like herself and created WatchHerWork. The company evolved to more, and now she's focused on diversity and inclusion consulting and leadership — and, amid COVID-19 and the resurgence of the Black Lives Matter movement, she's particularly busy now. Stream the episode and read more.

Chris DuPont, CEO of Galen Data

Houston-based Galen Data, led by Chris Dupont, is collaborating with an Austin health device company on a cloud-based platform that monitors vital signs. Photo via galendata.com

Houston-based Galen Data Inc., which has developed a cloud platform for medical devices, and Austin-based Advanced TeleSensors Inc., the creator of the Cardi/o touchless monitor. Together, the two health tech companies are collaborating to take ATS's device and adding Galen Data's cloud technology.

Chris DuPont, co-founder and CEO, has led the company to meet compliance standards set by the U.S. Food and Drug Administration (FDA), the Health Insurance Portability and Accountability Act of 1996 (HIPPA), cybersecurity organizations, and others.

"We knew that our platform would be a great fit for Cardi/o," Chris DuPont, CEO of Galen Data, says. "Speed was critical, accentuated by the COVID-19 crisis. We were well positioned to address ATS' needs, and help those at-risk in the process." Read more about the innovative Texas partnership.

Houston health tech startup with at-home COVID-19 test teams up with Texas university for research

be aware

An ongoing medical phenomenon is determining how COVID-19 affects people differently — especially in terms of severity. A new partnership between a Houston-based digital health platform and Texas A&M University is looking into differences in individual risk factors for the virus.

Imaware, which launched its at-home coronavirus testing kit in April, is using its data and information collected from the testing process for this new study on how the virus affects patients differently.

"As patient advocates, we want to aid in the search to understand more about why some patients are more vulnerable than others to the deadly complications of COVID-19," says Jani Tuomi, co-founder of imaware, in a press release. "Our current sample collection process is an efficient way to provide longitudinal prospectively driven data for research and to our knowledge, is the only such approach that is collecting, assessing, and biobanking specimens in real time."

Imaware uses a third-party lab to conduct the tests at patients' homes following the Center for Disease Control's guidelines and protocol. During the test, the medical professional takes additional swabs for the study. The test is then conducted by Austin-based Wheel, a telemedicine group.

Should the patient receive positive COVID-19 results, they are contacted by a representative of Wheel with further instructions. They are also called by a member of a team led by Dr. Rebecca Fischer, an infectious disease expert and epidemiologist and laboratory scientist at the Texas A&M University School of Public Health, to grant permission to be a part of the study.

Once a part of the study, the patient remains in contact with Fischer's team, which tracks the spread and conditions of the virus in the patient. One thing the researchers are looking for is the patients' responses to virus complications caused by an overabundance of cytokines, according to the press release. Cytokines are proteins in the body that fight viruses and infections, and, if not working properly, they can "trigger an over-exuberant inflammatory response" that can cause potentially deadly issues with lung and organ failure or worse, per the release.

"We believe strongly in supporting this research, as findings from the field can be implemented to improve clinical processes-- helping even more patients," says Wheel's executive medical director, Dr. Rafid Fadul.

View All Listings